|Slogan||The Human Data Science Company|
|Number of employees||~ 51-200|
Medicure is a speciality pharmaceutical Company engaged in the research, clinical development and commercialization of human therapeutics. The Company’s primary focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT® (tirofiban hydrochloride) in the United States and its territories through its U.S. subsidiary, Medicure Pharma Inc. The Company’s primary ongoing Research and Development activity is the development and implementation of a new brand and life cycle management strategy for AGGRASTAT®. The Company’s primary, non-AGGRASTAT® Research and Development activity is TARDOXAL for the treatment of Tardive Dyskinesia. Medicure’s vision is to become a leading cardiovascular pharmaceutical company within the U.S, offering a growing product portfolio of cardiovascular products that improve patients’ lives. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients, healthcare providers and shareholders. Our commitment to service, partnership and integrity is what sets us apart.
Medicure has an array of cardiovascular therapeutics available to both health care professionals and consumers alike.
In this section you will find an overview for each product that Medicure provides to the U.S.A. 
AGGRASTAT® (TIROFIBAN HYDROCHLORIDE) INJECTION
ZYPITAMAG® (PITAVASTATIN) TABLETS
SODIUM NITROPRUSSIDE INJECTION
Top 5 Lifetime Tweets